Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for
Go back to Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for| AGIOS PHARM (NASDAQ: AGIO) | Delayed: 35.10 +0.94 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.16 | 52 Week High | $71.49 | |||
| Open | $34.30 | 52 Week Low | $33.50 | |||
| Day High | $35.53 | P/E | N/A | |||
| Day Low | $34.30 | EPS | $-1.18 | |||
| Volume | 1,378,941 | |||||
